+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 14 Actively Recruiting clinical trials

U

Actively Recruiting

Researchers are evaluating how well a special imaging scan called 68Ga-FAPI-46 PETCT can predict the response of early-stage high-risk triple-negative breast cancer TNBC to treatment before starting therapy. This study focuses on patients receiving a combination of pembrolizumab, a type of immunotherapy, with chemotherapy as a standard care approach. The study is prospective and involves multiple centers collaborating to understand treatment outcomes better. Patients will receive pembrolizumab at a dose of 200 mg every three weeks alongside 4 cycles of paclitaxel plus carboplatin chemotherapy, followed by 4 cycles of either doxorubicin or epirubicin plus cyclophosphamide. After surgery to remove the tumor, participants will continue with up to 9 cycles of pembrolizumab as adjuvant therapy or until cancer returns or unacceptable side effects occur. Before treatment begins, each patient will have a 68Ga-FAPI-46 PETCT scan performed within 14 days, using the same machine as the standard 18F-FDG PETCT scan. During the study, researchers will collect imaging data and monitor patients throughout the entire treatment and follow-up period. They will assess how well the imaging scan predicts the tumors histological response to therapy by measuring outcomes such as the area under the ROC curve at 6 months. The study will also compare the predictive and prognostic performance of the 68Ga-FAPI-46 PETCT scan against the standard 18F-FDG PETCT scan. Participants will be followed closely for safety and treatment response during the neoadjuvant, surgical, and adjuvant phases of care, with the study ending by November 2032.

Age: 18Years +FEMALEPhase Not Applicable
6 locations
R

Actively Recruiting

Researchers are evaluating whether spesolimab helps adults with ulcerative pyoderma gangrenosum PG, a skin condition causing ulcers. The study focuses on whether spesolimab leads to the closure of PG ulcers and compares this with a placebo. This phase 3 clinical trial is randomized, double-blind, and placebo-controlled, enrolling adults with at least one ulcer between 5 cm and 80 cm in size. Participants are randomly assigned to receive either spesolimab or a placebo infusion every 4 weeks. In the first part of the study, all participants also take corticosteroid medicine by mouth for 8 weeks. In the second part, those without open ulcers are again randomly assigned to spesolimab or placebo, while participants with open ulcers receive spesolimab. The study includes two treatment phases to evaluate the effects under different conditions. Participants stay in the trial for about 1.5 years, attending around 20 study visits. During visits, doctors examine the skin for signs of PG, monitor overall health, and watch for any side effects. The main outcome is the complete closure of the target PG ulcer up to week 26, confirmed at a later visit. Secondary outcomes include pain reduction and quality of life improvements. The study compares results between groups to assess the treatments impact and monitors participants safety throughout.

Age: 18Years +All GendersPhase 3
104 locations
S

Actively Recruiting

Researchers are studying an experimental drug called linvoseltamab in adults newly diagnosed with symptomatic multiple myeloma who have not yet received treatment. The study aims to evaluate the safety, tolerability, and effectiveness of linvoseltamab, particularly how it may shrink tumors and work before and after stem cell transplant. This trial includes phases to find the right dosing and to monitor side effects and responses over time. Linvoseltamab is given by intravenous infusion in different dosing schedules. The study has several parts Phase 1 includes dose escalation and evaluation of alternative dosing regimens, while Phase 2 treats transplant-eligible participants for a fixed time and transplant-ineligible participants until disease progression with the selected dosing. The study evaluates linvoseltamab both before and after autologous stem cell transplantation. Participants will be closely monitored through various assessments including tracking side effects, measuring drug levels in the blood, and checking for antibodies against the drug. Response to treatment is measured by tumor shrinkage and minimal residual disease status up to five years. Safety monitoring continues up to 90 days after the last dose, with long-term follow-up for treatment effectiveness and survival. The study duration varies depending on transplant eligibility and treatment response.

Age: 18Years +All GendersPhase 1Phase 2
32 locations
R

Actively Recruiting

Researchers are evaluating brivekimig in a Phase 2b study for people with moderate to severe hidradenitis suppurativa HS, a chronic skin condition. The study is designed to test the safety and effectiveness of different doses of brivekimig compared to a placebo. This global, multicenter trial uses a randomized, double-blind, placebo-controlled, parallel group design to ensure reliable results. Participants receive one of three brivekimig dose regimens or a matching placebo through subcutaneous injections. The main studys randomized treatment period can last up to approximately 152 weeks. Some participants may continue into a long-term extension lasting up to about 164 weeks, while others will complete the study by around 60 weeks. Throughout the study, participants are monitored regularly for treatment response using measures like the Hidradenitis Suppurativa Clinical Response HiSCR75 up to Week 16. Researchers also assess skin pain, quality of life, and skin lesion changes. Safety is tracked through adverse event reporting and laboratory tests for up to the studys end. Overall participation can last up to 164 weeks depending on extension study involvement.

Age: 18Years +All GendersPhase 2
85 locations
O

Actively Recruiting

This observational study involves patients diagnosed with chronic myelomonocytic leukemia, a type of leukemia characterized by increased monocytes in the blood. The purpose is to better understand the diseases underlying mechanisms, with data collected over an average of 15 years. Biological samples and anonymized data will be gathered during routine care or clinical trials to support this research. The study is sponsored by Gustave Roussy, Cancer Campus, Grand Paris. Participants will have biological samples collected, including blood and bone marrow, during scheduled medical assessments. Blood samples include standard tubes and may vary based on research needs, while bone marrow samples are taken during routine myelograms. In exceptional cases, tissue samples may be collected during surgical procedures if agreed upon with the surgeon. These collections occur alongside usual medical care without additional interventions. Throughout the study, participants will undergo sample collections aligned with their medical visits and tests. Researchers will analyze these samples and associated anonymized data to study the diseases pathophysiology. Participation involves no investigational treatments, and the study will monitor participants for up to 15 years to gather long-term data. Safety and routine care continue as usual during this period.

Age: 18Years +All Genders
24 locations
S

Actively Recruiting

Healthy Volunteer

This research investigates how Mucosal-Associated Invariant T MAIT cells interact with the gut microbiota and mucosa in children with or at risk of type 1 diabetes T1D. It evaluates changes in MAIT cell frequency, function, and phenotype, linking them to gut health, the presence of Coxsackie virus B, and T1D development. The study involves pediatric patients recently diagnosed with T1D, those at high genetic risk, and control groups. Participants are grouped into recent-onset T1D patients, at-risk siblings with specific genetic markers, control patients without T1D risk, and controls undergoing upper gastrointestinal UGI endoscopy for other medical reasons. The study collects blood, stool, and urine samples to analyze MAIT cells, gut microbiota, viral infection, and gut integrity. Selected patients undergo UGI endoscopy for duodenal biopsies to study mucosal changes. Participants provide samples at enrollment, including blood for MAIT cell and antibody analyses, stool for microbiota and viral testing, and urine for gut permeability tests. Some undergo endoscopy for tissue biopsies. Researchers assess immune markers, gut mucosa health, and viral presence, aiming to understand MAIT cells as biomarkers for T1D progression. The study lasts until August 2027, with data collected mainly at enrollment and in selected subgroups.

Age: 12Months - 15YearsAll Genders
2 locations
O

Actively Recruiting

Researchers are studying adult patients with unresectable or metastatic HER2-low and HER2-ultralow expressing breast cancer who have either received prior chemotherapy in the metastatic setting or have hormone receptor-positive disease not suitable for endocrine therapy. The study aims to observe the real-world use and effects of Trastuzumab deruxtecan T-DXd and conventional chemotherapy in these populations. This observational study collects data without administering any study drugs directly, focusing on patient characteristics, treatment patterns, and safety. Participants will be grouped into those receiving T-DXd according to approved medical guidelines and those treated with conventional chemotherapy, including drugs like capecitabine and paclitaxel. The study records treatment details and the management of any adverse reactions, with Group 2 patients contributing baseline data on conventional chemotherapy. Treatments are given as part of routine clinical care, following the Summary of Product Characteristics, without experimental interventions. During the study, participants treatment courses will be tracked for up to approximately 37 months. Researchers will evaluate the time to next treatment, treatment discontinuation, safety events, and patients impressions of treatment tolerability and quality of life. Data collection includes physician reports, patient diaries, and quality of life questionnaires. This long-term monitoring helps to understand treatment patterns and patient experiences in real-world settings.

Age: 18Years +All Genders
216 locations
I

Actively Recruiting

Neurological disorders like cerebral palsy can cause significant motor challenges that affect daily life, especially in children. This research evaluates the use of intensive, repetitive training focused on reach-to-grasp movements to improve hand function in children aged 4 to 17 years with such motor impairments. The study explores a new approach combining serious gaming with physical training to make repetitive therapy more engaging and effective. Participants will engage in a 4-week intervention involving three 40-minute sessions per week using a specialized serious game. This game includes software, a physical platform, and instrumented toys designed to encourage grasp-and-release and reach-to-grasp actions through repeated movements. The therapy aims to provide about 4 hours of gameplay, with sessions including specific tasks like the Box and Blocks Test and range of motion exercises. Children will first complete baseline assessments measuring manual dexterity and wrist movement, along with the Assisting Hand Assessment. After the intervention, these tests will be repeated, and a follow-up evaluation will occur two months later to measure lasting effects. Researchers will track improvements using the Box and Blocks Test, active wrist range of motion, and the Assisting Hand Assessment to understand the therapys impact.

Age: 4Years - 17YearsAll GendersPhase Not Applicable
2 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the effectiveness of the Apneal4 app on smartphones for diagnosing sleep apnea syndrome SAS in adults who require polysomnography PSG as part of their routine care. The study aims to determine if Apneal4 can accurately classify SAS severity into four categories, estimate the Apnea-Hypopnea Index AHI, detect sleep stages, differentiate between central and obstructive apneas, and identify patient movements compared to PSG. Participants will wear a smartphone equipped with the Apneal4 app on their chest during a full night of sleep at home while undergoing polysomnographic recording. They will also complete several questionnaires assessing sleep symptoms and their experience with the Apneal4 app. The study will monitor these measures over an average of one year to evaluate device performance and patient acceptability. During the study, participants will be assessed using both the Apneal4 device and standard PSG. Researchers will compare Apneal4 results with screening questionnaires like NoSAS, Berlin, and Epworth. Participants will complete questionnaires about their sleep symptoms and the devices ease of use. The primary outcome is the performance of Apneal4 in diagnosing sleep apnea-hypopnea syndrome. Safety and feasibility will be monitored throughout the study, which is expected to last about one year per participant.

Age: 18Years +All GendersPhase Not Applicable
11 locations
P

Actively Recruiting

Healthy Volunteer

The program GR-Ex, designated by the French Ministry of Higher Education and Research, focuses on improving understanding of how red blood cells, erythropoiesis, and iron metabolism work in both normal and disease states. It aims to develop innovative therapeutic approaches that offer meaningful advancements in treatment. This observational study involves collecting biological samples from patients with red blood cell disorders and their relatives to support research. Participants provide various biological samples including blood, saliva, urine, surgical remnants like skin or tumor tissue, and hair. Samples are collected both from affected patients and their non-affected relatives to help explore different aspects of red blood cell physiology and related diseases. The study is designed to run over many years to capture long-term data. Throughout the study, researchers will analyze multiple outcomes such as markers of spleen function, inflammation in sickle cell disease, hemolysis after artesunate treatment, and iron metabolism in specific anemias. They will also investigate the effects of treatments like phosphodiesterase inhibitors on cell adhesion and the removal of mitochondria during red blood cell formation. Participants may be involved in providing samples over extended periods, with ongoing monitoring to collect data relevant to these primary outcomes.

All AgesAll Genders
25 locations

1-10 of 14

1